Trial Information
Impact of C-arm CT in Patients With Decreased Renal Function Undergoing Transhepatic Arterial Chemoembolization (TACE) for the Treatment of Hepato-Cellular Carcinoma
Inclusion Criteria:
1. Patients must be affected by HCC
2. Patients must have diminished renal function (GFR<60 ml/min/1.73m^2)
3. Patients must be 18 years old or older
4. Patients must have received an abdominal CT, PET/CT scan or MRI, completed prior to
the TACE procedure.
5. Ability to understand and the willingness to sign a written informed consent
document.
Exclusion Criteria:
1. Subjects under the age of 18
2. Patients currently on dialysis
3. Pregnant women
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Proportion of patients that develop renal failure (defined as a decline of renal function, as measured by glomerular filtration rate, of 25% or more from pre-procedural)
Outcome Time Frame:
3 weeks
Safety Issue:
No
Principal Investigator
Nishita N. Kothary
Investigator Role:
Principal Investigator
Investigator Affiliation:
Stanford University
Authority:
United States: Institutional Review Board
Study ID:
HEP0035
NCT ID:
NCT01326390
Start Date:
May 2010
Completion Date:
September 2012
Related Keywords:
- Kidney (Renal Cell) Cancer
- Carcinoma
- Carcinoma, Renal Cell
- Carcinoma, Hepatocellular
Name | Location |
Stanford University School of Medicine |
Stanford, California 94305-5317 |